Vistagen therapeutics stock.
Insiders who bought stock earlier this year lose -US$12k as VistaGen Therapeutics, Inc. (NASDAQ:VTGN) drops to US$34m. (Simply Wall St.) Sep-20-22 08:30AM. Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit.
VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 9,622,300 $ 16,637,600 Prepaid expenses and other current assets 1,889,400 802,700Mar 9, 2023 · Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 thousand and a GAAP net loss of $9.76 million. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small ...On average, Wall Street analysts predict that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock ...Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of …
On average, Wall Street analysts predict. that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock price prediction forecasts a potential upside of 484.96% from the current VTGN share price of $3.59.
See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive feedback from its recent engagement with the U.S. Food and Drug Administration (FDA) regarding the use of the Liebowitz Social Anxiety Scale (LSAS) as the ...About the VistaGen Therapeutics, Inc. stock forecast. As of 2023 November 29, Wednesday current price of VTGN stock is 3.600$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. VistaGen Therapeutics stock price as been showing a rising tendency so we believe …VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ...
VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 9,622,300 $ 16,637,600 Prepaid expenses and other current assets 1,889,400 802,700
Oct 2, 2023 · By Colin Kellaher. Vistagen Therapeutics shares tumbled on Monday after the clinical-stage biopharmaceutical company said it was raising $100 million in a public offering of stock and warrants.
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the last participant has completed the study protocol in its U.S. Phase 1 clinical trial of itruvone (PH10), the …Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced that the last participant has completed the study protocol in its U.S. Phase 1 clinical trial of itruvone (PH10), the …VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities. Vistagen Therapeutics Inc (VTGN) stock has risen 14.79% while the S&P 500 is down -0.56% as of 12:54 PM on Monday, Dec 4. VTGN is up $0.54 from the previous closing price of $3.65 on volume of 899,778 shares. Over the past year the S&P 500 has gained 14.26% while VTGN is up 12.03%. VTGN lost -$4.76 per share the over the last …The recent price decline of 15% in VistaGen Therapeutics, Inc.'s (NASDAQ:VTGN) stock may have disappointed insiders who bought US$190k worth of shares at an average price of US$0.17 in the past 12 ...
SOUTH SAN FRANCISCO, Calif., October 02, 2023--Vistagen Therapeutics, Inc. ("Vistagen") (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape ...Moreover, Shawn Singh also holds US$83k worth of VistaGen Therapeutics stock directly under their own name. Component. 2022. 2021. Proportion (2022) Salary. US$563k. US$511k. 48%. Other. US$620k.Biotech Firm Pops 677% on Social Anxiety Spray Trial Success. A beaten down micro-cap biotech company, Vistagen Therapeutics Inc., notched its best day ever, surging by as many as four digits ...Vistagen Therapeutics ( NASDAQ: VTGN) added ~17% on Tuesday after Stifel initiated its coverage with a Buy recommendation citing a potential blockbuster opportunity for its anxiety disorder drug ...Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...
H Snodgrass VTGN stock SEC Form 4 insiders trading. H has made over 3 trades of the VistaGen Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,750 units of VTGN stock worth $10,238 on 17 August 2021.. The largest trade he's ever made was buying 15,000 units of VistaGen …
There are 137 funds or institutions reporting positions in VistaGen Therapeutics. This is a decrease of 34 owner (s) or 19.88% in the last quarter. Average portfolio weight of all funds dedicated ...SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 6, 2023-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call …Stock split history for VistaGen Therapeutics.The stock appears to be pulling back after soaring more than 675% on Monday . What Happened: VistaGen shares surged Monday after the company said its Phase 3 PALISADE-2 trial of fasedienol nasal ...According to the U.S. Food and Drug Administration (FDA), a drug with a narrow therapeutic range (NTI) is one with a narrow range between the drug’s risks and its benefits. The NTI is also known a narrow therapeutic index or critical dose d...Dec 1, 2023 · VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss SA News Fri, Aug. 12, 2022 2 Comments VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M ... Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.Vistagen Therapeutics, Inc. 3.6500 +0.0600 +1.67%: TRENDING. 1. ... As U.S. stocks sit on hefty gains at the close of a rollercoaster year, investors are eyeing factors that could sway equities in ...On average, Wall Street analysts predict. that Vistagen Therapeutics's share price could reach $21.00 by Nov 14, 2024. The average Vistagen Therapeutics stock price prediction forecasts a potential upside of 484.96% from the current VTGN share price of $3.59.Stock Price Forecast The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00.
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.
Vistagen (NASDAQ:VTGN) to implement a stockholder-approved a one-for-thirty reverse stock split of its outstanding shares of common stock, effective June 7, 2023.The primary corporate and ...
Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis. Oct 2, 2023 · At a combined purchase price of $5.38 per share of common stock, accompanying T1 Warrant and accompanying T2 Warrant (as defined below), the offering consists of 15,010,810 shares of Vistagen common stock, accompanying warrants to purchase up to 9,294,022 shares of Vistagen common stock (or pre-funded warrants in lieu thereof) at an exercise ... Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those currently …Aug 7, 2023 · Vistagen Therapeutics (NASDAQ: VTGN) stock is surging to impressive levels today on news of some positive trial results. The pharmaceutical producer has been struggling all year, dipping into ... VistaGen Therapeutics - VTGN - Stock Price Today - Zacks VistaGen Therapeutics (VTGN) (Delayed Data from NSDQ) $2.73 USD +0.16 (6.23%) Updated …VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities. Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.VistaGen Therapeutics Inc (VTGN) Share Price and News. VistaGen Therapeutics, Inc. (NASDAQ: VTGN), is a clinical-stage biopharmaceutical company developing.
Vistagen to conduct small U.S. Phase 1 trial with newly optimized formulation of PH10 in Q1 2023 to confirm favorable safety profile from three previous clinical trials and to facilitate Phase 2B development of PH10 for major depressive disorder. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 30, 2022-- Vistagen, (NASDAQ: …7.32%. $1.48B. VTGN | Complete VistaGen Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued.Instagram:https://instagram. iphone 15 cloneinvesting in spacexncr corporation stockdsx dividends Discover historical prices for VTGN stock on Yahoo Finance. View daily, weekly or monthly format back to when Vistagen Therapeutics, Inc. stock was issued. waterline insurance coveragebudget desk Analyst Recommendations on Vistagen Therapeutics, Inc. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. 2022. MT. William Blair Downgrades VistaGen Therapeutics to Market Perform From Outperform. 2022.Based on short-term price targets offered by two analysts, the average price target for VistaGen Therapeutics, Inc. comes to $12.00. The forecasts range from a low of $12.00 to a high of $12.00 ... dia stok Get Vistagen Therapeutics Inc (VTGN.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Vistagen common stock will begin trading. SOUTH SAN FRANCISCO, Calif., June 06, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment ...In health-care professions, “therapeutic use of self” describes the ability of a caregiver to use his or her personality “consciously and in full awareness in an attempt to establish relatedness and to structure nursing interventions,” acco...